Literature DB >> 19199004

Tonsillary carcinoma after temozolomide treatment for glioblastoma multiforme: treatment-related or dual-pathology?

E Binello1, I M Germano.   

Abstract

Glioblastoma multiforme is a primary malignant brain tumor with a prognosis of typically less than 2 years. Standard treatment paradigms include surgery, radiation therapy and temozolomide. Little data exists for temozolomide recommendations after the first 6 months. We present a case of a patient with glioblastoma multiforme treated with surgery, radiation and chronic temozolomide for 6 years. He continues to survive glioblastoma-recurrence-free, but developed tonsillary carcinoma. This case raises the question of whether this secondary solid-organ malignancy is treatment-related or dual pathology.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19199004     DOI: 10.1007/s11060-009-9806-7

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  14 in total

1.  Aplastic anaemia in patient with glioblastoma multiforme treated with temozolomide.

Authors:  J Lee Villano; Cindy A Collins; Elisabet E Manasanch; Charulata Ramaprasad; Koen van Besien
Journal:  Lancet Oncol       Date:  2006-05       Impact factor: 41.316

Review 2.  Treatment-related myelodysplasia/AML in a patient with a history of breast cancer and an oligodendroglioma treated with temozolomide: case study and review of the literature.

Authors:  Vanita Noronha; Nancy Berliner; Karen K Ballen; Jill Lacy; Jean Kracher; Joachim Baehring; John W Henson
Journal:  Neuro Oncol       Date:  2006-05-25       Impact factor: 12.300

3.  Mutagenic potential of temozolomide in bone marrow cells in vivo.

Authors:  Hartmut Geiger; David Schleimer; Kalpana J Nattamai; Stefanie R Dannenmann; Stella M Davies; Brian D Weiss
Journal:  Blood       Date:  2006-04-01       Impact factor: 22.113

Review 4.  Current management of tonsillar cancer.

Authors:  Eric M Genden; Alfio Ferlito; Crispian Scully; Ashok R Shaha; Kevin Higgins; Alessandra Rinaldo
Journal:  Oral Oncol       Date:  2003-06       Impact factor: 5.337

Review 5.  Treatment-related myelodysplastic syndrome after temozolomide for recurrent high-grade glioma.

Authors:  Ying-Wen Su; Ming-Chih Chang; Ming-Fu Chiang; Ruey-Kuen Hsieh
Journal:  J Neurooncol       Date:  2005-02       Impact factor: 4.130

6.  Role of autophagy in temozolomide-induced cytotoxicity for malignant glioma cells.

Authors:  T Kanzawa; I M Germano; T Komata; H Ito; Y Kondo; S Kondo
Journal:  Cell Death Differ       Date:  2004-04       Impact factor: 15.828

7.  Inhibition of DNA repair for sensitizing resistant glioma cells to temozolomide.

Authors:  Takao Kanzawa; Joshua Bedwell; Yasuko Kondo; Seiji Kondo; Isabelle M Germano
Journal:  J Neurosurg       Date:  2003-12       Impact factor: 5.115

8.  Unexpected case of aplastic anemia in a patient with glioblastoma multiforme treated with Temozolomide.

Authors:  Rakesh Jalali; Pritanjali Singh; Hari Menon; Sumeet Gujral
Journal:  J Neurooncol       Date:  2007-05-16       Impact factor: 4.130

9.  Tonsillar carcinoma in a renal graft recipient treated with cyclosporine A.

Authors:  A Swoboda; V Fabrizii
Journal:  Clin Nephrol       Date:  1993-05       Impact factor: 0.975

10.  Canadian recommendations for the treatment of glioblastoma multiforme.

Authors:  W P Mason; R Del Maestro; D Eisenstat; P Forsyth; D Fulton; N Laperrière; D Macdonald; J Perry; B Thiessen
Journal:  Curr Oncol       Date:  2007-06       Impact factor: 3.677

View more
  1 in total

1.  Tonsillar pseudotumor: complications of chronically-administered temozolomide.

Authors:  Kathleen Grisdale; Melesa Ritterhouse; Kathy Hunter; Michelle D Williams; Morris D Groves
Journal:  J Neurooncol       Date:  2010-05-04       Impact factor: 4.130

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.